Modality
Vaccine
MOA
Menini
Target
BCL-2
Pathway
T-cell
HS
Development Pipeline
Preclinical
~Jul 2020
→ ~Oct 2021
Phase 1
~Jan 2022
→ ~Apr 2023
Phase 2
Jul 2023
→ Oct 2030
Phase 2Current
NCT05140292
644 pts·HS
2023-07→2030-10·Completed
644 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-10-204.6y awayPh2 Data· HS
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2
Complet…
Catalysts
Ph2 Data
2030-10-20 · 4.6y away
HS
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05140292 | Phase 2 | HS | Completed | 644 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-4339 | Argenx | Phase 2 | BCL-2 | |
| GMA-729 | Genmab | Phase 2 | BCL-2 | |
| HAL-996 | Halozyme | Phase 1/2 | BCL-2 | |
| Bemaderotide | Revolution Medicines | Phase 3 | BCL-2 | |
| Olpafutibatinib | Immunocore | Approved | SMN2 |